Improving patient outcomes through innovations in biological therapeutics
ImmunoBiochem is an innovative biopharmaceutical company on a mission to develop novel biological therapeutics to address significant unmet need in oncology and immuno-oncology. ImmunoBiochem is unravelling unique biology in the tumor microenvironment with the goal of discovering novel therapeutic targets and strategies. ImmunoBiochem, a Johnson & Johnson Innovation (JLABS) alumnus, is headquartered in Toronto, at the heart of Canada’s largest biomedical research hub.
Science & Technology Platform
ImmunoBiochem utilizes a combination of high-throughput functional assays, mass spectrometry and AI/ML to unravel unique biology in the tumor microenvironment, particularly in the cancer cell secretome – the totality of proteins secreted by cancer cells. This proprietary technology platform enables the discovery of novel tumor targets with unique behaviours in tumors that could be exploited with various targeted therapeutic modalities.
ImmunoBiochem has leveraged such novel cancer secretome targets to engender new strategies for the selective and efficacious delivery of potent chemotherapeutic and immunomodulatory payloads to a variety of cells within the tumor, including cancer cells, supporting stroma and different immune system cells. This targeting approach overcomes the challenges of solid tumor heterogeneity, tumor penetration, intratumoral distribution, and target-mediated resistance mechanisms that are commonly faced by biological therapeutics, with the ultimate goal to significantly improve efficacy against intractable solid tumors.